Author: Fabrizio Schifano
Publisher: Frontiers Media SA
ISBN: 2889669408
Category : Medical
Languages : en
Pages : 141
Book Description
Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction
Author: Fabrizio Schifano
Publisher: Frontiers Media SA
ISBN: 2889669408
Category : Medical
Languages : en
Pages : 141
Book Description
Publisher: Frontiers Media SA
ISBN: 2889669408
Category : Medical
Languages : en
Pages : 141
Book Description
Novel Psychoactive Substances
Author: Ornella Corazza
Publisher: Springer
ISBN: 331960600X
Category : Business & Economics
Languages : en
Pages : 192
Book Description
In light of the recent emergence of Novel Psychoactive Substances (NPS) on a global scale, this book provides a timely analysis of the social and economic impact of the NPS phenomenon, and of the global policy and regulatory responses to it. It presents the first comprehensive overview of the international regulation, policy and market structure of the NPS phenomenon, offering a guide to inform legislative discussions and demonstrating from a comparative perspective the different approaches used to address the rise of NPS to date. It covers topics such as organized crime, drug markets, clinical evidence on NPS, and different regulatory approaches also in less explored settings such as prisons and sport environments. Overall, this highly informative and well-structured repository of different experiences with NPS policy, law and regulation offers an essential primary source of evidence for anyone interested in the area of drug and NPS policy, health economics and p ublic health.
Publisher: Springer
ISBN: 331960600X
Category : Business & Economics
Languages : en
Pages : 192
Book Description
In light of the recent emergence of Novel Psychoactive Substances (NPS) on a global scale, this book provides a timely analysis of the social and economic impact of the NPS phenomenon, and of the global policy and regulatory responses to it. It presents the first comprehensive overview of the international regulation, policy and market structure of the NPS phenomenon, offering a guide to inform legislative discussions and demonstrating from a comparative perspective the different approaches used to address the rise of NPS to date. It covers topics such as organized crime, drug markets, clinical evidence on NPS, and different regulatory approaches also in less explored settings such as prisons and sport environments. Overall, this highly informative and well-structured repository of different experiences with NPS policy, law and regulation offers an essential primary source of evidence for anyone interested in the area of drug and NPS policy, health economics and p ublic health.
The Maudsley Deprescribing Guidelines
Author: David M. Taylor
Publisher: John Wiley & Sons
ISBN: 111982298X
Category : Medical
Languages : en
Pages : 597
Book Description
Comprehensive resource describing guidelines for safely reducing or stopping (deprescribing) antidepressants, benzodiazepines, gabapentinoids and z-drugs for patients, including step-by-step guidance for all commonly used medications, covering common pitfalls, troubleshooting, supportive strategies, and more. Most formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so. The Maudsley Deprescribing Guidelines fills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment. The evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts). Building on the recognised brand of The Maudsley Prescribing Guidelines, and the prominence of the authors' work, including in The Lancet Psychiatry on tapering antidepressants (the most read article across all Lancet titles when it was released). The Maudsley Deprescribing Guidelines covers topics such as: Why and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs Barriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process Distinguishing withdrawal symptoms from dose reduction, such as poor mood, anxiety, and insomnia, from symptoms of the underlying disorder that medication was intended to treat The difference between physical dependence and addiction/substance use disorder Explanation of why and how to implement hyperbolic tapering in clinical practice Specific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches Step-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual Troubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse. Written for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. The Maudsley Deprescribing Guidelines is an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine.
Publisher: John Wiley & Sons
ISBN: 111982298X
Category : Medical
Languages : en
Pages : 597
Book Description
Comprehensive resource describing guidelines for safely reducing or stopping (deprescribing) antidepressants, benzodiazepines, gabapentinoids and z-drugs for patients, including step-by-step guidance for all commonly used medications, covering common pitfalls, troubleshooting, supportive strategies, and more. Most formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so. The Maudsley Deprescribing Guidelines fills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment. The evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts). Building on the recognised brand of The Maudsley Prescribing Guidelines, and the prominence of the authors' work, including in The Lancet Psychiatry on tapering antidepressants (the most read article across all Lancet titles when it was released). The Maudsley Deprescribing Guidelines covers topics such as: Why and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs Barriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process Distinguishing withdrawal symptoms from dose reduction, such as poor mood, anxiety, and insomnia, from symptoms of the underlying disorder that medication was intended to treat The difference between physical dependence and addiction/substance use disorder Explanation of why and how to implement hyperbolic tapering in clinical practice Specific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches Step-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual Troubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse. Written for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. The Maudsley Deprescribing Guidelines is an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine.
National Survey on Drug Abuse
Author:
Publisher:
ISBN:
Category : Drug abuse
Languages : en
Pages : 170
Book Description
Publisher:
ISBN:
Category : Drug abuse
Languages : en
Pages : 170
Book Description
Guidelines for the Control of Narcotic and Psychotropic Substances
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9241541725
Category : Law
Languages : en
Pages : 144
Book Description
Publisher: World Health Organization
ISBN: 9241541725
Category : Law
Languages : en
Pages : 144
Book Description
Substance Abuse Among Older Adults
Author:
Publisher:
ISBN:
Category : Older people
Languages : en
Pages : 204
Book Description
Publisher:
ISBN:
Category : Older people
Languages : en
Pages : 204
Book Description
Case Studies in Pain Management
Author: Alan David Kaye
Publisher: Cambridge University Press
ISBN: 1107682894
Category : Medical
Languages : en
Pages : 547
Book Description
Edited by internationally recognized pain experts, this book offers 73 clinically relevant cases, accompanied by discussion in a question-and-answer format.
Publisher: Cambridge University Press
ISBN: 1107682894
Category : Medical
Languages : en
Pages : 547
Book Description
Edited by internationally recognized pain experts, this book offers 73 clinically relevant cases, accompanied by discussion in a question-and-answer format.
Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care
Author:
Publisher:
ISBN:
Category : Drug traffic
Languages : en
Pages : 356
Book Description
Publisher:
ISBN:
Category : Drug traffic
Languages : en
Pages : 356
Book Description
The Benzo Book
Author: Jack Hobson-Dupont
Publisher: Lulu.com
ISBN: 1411692594
Category : Science
Languages : en
Pages : 262
Book Description
FROM THE BACK COVER: Are you--or is someone you care about--taking tranquilizers or sleeping pills? You could be at risk of addiction without even knowing it. Benzos are the most commonly prescribed tranquilizers and sleeping pills, in use by millions of people. Doctors prescribe these drugs routinely without ever warning patients that regular use may cause a dangerous dependency. For many people, Benzos are much harder to quit than heroin, cocaine, crack and other illegal substances, even when taken under a physician's supervision. Benzo Withdrawal may last for months, even years. Get the facts about the drugs in your medicine cabinet--facts the pharmaceutical companies, and even the FDA, don't want you to know. The Benzo Book recounts the author's experience as an unwitting addict, with full details about minimizing withdrawal symptoms, and exposes the sociological, medical and economic factors which cause this widespread--yet largely unknown--problem.
Publisher: Lulu.com
ISBN: 1411692594
Category : Science
Languages : en
Pages : 262
Book Description
FROM THE BACK COVER: Are you--or is someone you care about--taking tranquilizers or sleeping pills? You could be at risk of addiction without even knowing it. Benzos are the most commonly prescribed tranquilizers and sleeping pills, in use by millions of people. Doctors prescribe these drugs routinely without ever warning patients that regular use may cause a dangerous dependency. For many people, Benzos are much harder to quit than heroin, cocaine, crack and other illegal substances, even when taken under a physician's supervision. Benzo Withdrawal may last for months, even years. Get the facts about the drugs in your medicine cabinet--facts the pharmaceutical companies, and even the FDA, don't want you to know. The Benzo Book recounts the author's experience as an unwitting addict, with full details about minimizing withdrawal symptoms, and exposes the sociological, medical and economic factors which cause this widespread--yet largely unknown--problem.
Federal Guidelines for Opioid Treatment Programs
Author: U.S. Department of Health and Human Services
Publisher: Lulu.com
ISBN: 1794763538
Category : Reference
Languages : en
Pages : 84
Book Description
The Federal Guidelines for Opioid Treatment Programs (Guidelines) describe the Substance Abuse and Mental Health Services Administration's (SAMHSA) expectation of how the federal opioid treatment standards found in Title 42 of the Code of Federal Regulations Part 8 (42 CFR ยง 8) are to be satisfied by opioid treatment programs (OTPs). Under these federal regulations, OTPs are required to have current valid accreditation status, SAMHSA certification, and Drug Enforcement Administration (DEA) registration before they are able to administer or dispense opioid drugs for the treatment of opioid addiction.
Publisher: Lulu.com
ISBN: 1794763538
Category : Reference
Languages : en
Pages : 84
Book Description
The Federal Guidelines for Opioid Treatment Programs (Guidelines) describe the Substance Abuse and Mental Health Services Administration's (SAMHSA) expectation of how the federal opioid treatment standards found in Title 42 of the Code of Federal Regulations Part 8 (42 CFR ยง 8) are to be satisfied by opioid treatment programs (OTPs). Under these federal regulations, OTPs are required to have current valid accreditation status, SAMHSA certification, and Drug Enforcement Administration (DEA) registration before they are able to administer or dispense opioid drugs for the treatment of opioid addiction.